QWM
VKTX icon

Quaker Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Quaker Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.7K Hold
2,880
– – 0.03% 115
2025
Q4 		$101K Hold
2,880
– – 0.03% 117
2025
Q3 		$75.7K Hold
2,880
– – 0.02% 127
2025
Q2 		$76.3K Buy
+2,880
New +$75.8K 0.03% 126

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Quaker Wealth Management's VKTX Position: Q1 2026 in Review

Quaker Wealth Management held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 2,880 shares worth $93.7K. The position accounts for 0.03% of the portfolio, ranked #115.

Quaker Wealth Management first reported a position in VKTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $101K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Quaker Wealth Management held 2,880 shares of Viking Therapeutics worth $93.7K as of Q1 2026.
  • Quaker Wealth Management left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up 0.03% of Quaker Wealth Management's portfolio in Q1 2026, its #115 holding.
  • Quaker Wealth Management first reported a position in Viking Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Quaker Wealth Management's Viking Therapeutics position peaked at $101K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Quaker Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.